Adverse effects of immunoglobulin therapy
Authors:
Iva Šutová; Zita Chovancová; Jiří Litzman
Authors‘ workplace:
Ústav klinické imunologie a alergologie LF MU a FN u sv. Anny v Brně
Published in:
Vnitř Lék 2019; 65(2): 131-135
Category:
Overview
Immunoglobulin products contain specific antibodies in IgG class which are directed against wide range of pathogens. These products are obtained from plasma of healthy donors. Immunoglobulin derivates can be administrated by intravenous or subcutaneous route in substitution or immunomodulation indications. The administration can be accompanied by a risk of adverse events. The most common are pyretic reactions, chills, headache, nausea, malaise and muscle pain, nevertheless also severe systemic reactions can occur. Almost one third of the reactions appear during the first administration. The number and severity of reactions depends on administered dose, speed and the application way. Pre-existing comorbidities of the patients and presence of acute infection are also an important risk factors for adverse reactions. Therapy of side effects is mostly symptomatic.
Keywords:
Adverse events – anaphylaxis – intravenous immunoglobulins – subcutaneous immunoglobulins
Sources
1. Bruton OC. Agammaglobulinemia. Pediatrics 1952; 9(6): 722–728.
2. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008; 28: 737–764, viii. Dostupné z DOI: <http://dx.doi.org/10.1016/j.iac.2008.06.004>.
4. Perez EE, Orange JS, Bonilla F et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol 2017; 139(3S): S1-S46. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2016.09.023>.
5. Gelfand EW. Critical decisions in selecting an intravenous immunoglobulin product. J Infus Nurs 2005; 28(6): 366–374.
6. Simon HU, Späth PJ. IVIG – mechanisms of action. Allergy 2003; 58(7): 543–552.
7. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38(1–3): 122–132.
8. Negi VS, Elluru S, Sibéril S et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007; 27(3): 233–245. Dostupné z DOI: <http://dx.doi.org/10.1007/s10875–007–9088–9>.
9. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008; 28: 413–437, x. Dostupné z DOI: <http://dx.doi.org/10.1016/j.iac.2008.01.008>.
10. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol 2008; 101(2): 114–121; quiz 122–123, 78. Dostupné z DOI: <http://dx.doi.org/10.1016/S1081–1206(10)60197–4>.
11. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008; 28(4): 803–819. Dostupné z DOI: <http://dx.doi.org/10.1016/j.iac.2008.06.006>.
12. Azizi G, Abolhassani H, Asgardoon MH et al. Managing patients with side effects and adverse events to immunoglobulin therapy. Expert Rev Clin Pharmacol 2016; 9(1): 91–102. Dostupné z DOI: <http://dx.doi.org/10.1586/17512433.2016.1105131>.
13. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013; 27(3): 171–178. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tmrv.2013.05.004>.
16. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003; 17(4): 241–251.
17. Orbach H, Katz U, Sherer Y et al. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29(3): 173–184. Dostupné z DOI: <http://dx.doi.org/10.1385/CRIAI:29:3:173>.
18. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008; 122(6): 1238–1239. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2008.08.033>.
19. Bichuetti-Silva DC, Furlan FP, Nobre FA et al. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. Int Immunopharmacol 2014; 23(2): 442–446. Dostupné z DOI: <http://dx.doi.org/10.1016/j.intimp.2014.09.015>.
20. Berard R, Whittemore B, Scuccimarri R. Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases. Pediatr Rheumatol Online J 2012; 10(1): 10. Dostupné z DOI: <http://dx.doi.org/10.1186/1546–0096–10–10>.
21. Bonagura VR, Marchlewski R, Cox A et al. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122(1): 210–212. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2008.04.044>.
22. Pautard B, Hachulla E, Bagot d‘Arc M et al. Intravenous immunoglobulin (Endobulin) clinical tolerance: prospective therapeutic follow-up of 142 adults and children. Rev Med Interne 2003; 24(8): 505–513.
23. Brennan VM, Salomé-Bentley NJ, Chapel HM et al. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003; 133(2): 247–251.
24. Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child 2006; 91(8): 651–654. Dostupné z DOI: <http://dx.doi.org/10.1136/adc.2005.078733>.
25. Schroeder HW, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection 2012; 40(6): 601–611. Dostupné z DOI: <http://dx.doi.org/10.1007/s15010–012–0323–9>.
26. Bonilla FA. Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc 2016; 37(6): 426–431.
27. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007; 21(2): 105–116. Dostupné z DOI: <http://dx.doi.org/10.2165/00063030–200721020–00005>.
28. Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol Pract 2013; 1(6): 558–566. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaip.2013.09.012>.
29. Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 2007; 96(10): 1474–1478. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1651–2227.2007.00485.x>.
31. Vultaggio A, Azzari C, Milito C et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig 2015; 35(3): 179–185. Dostupné z DOI: <http://dx.doi.org/10.1007/s40261–015–0270–1>.
34. de Albuquerque Campos R, Sato MN, da Silva Duarte AJ. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol 2000; 20(1): 77–82.
40. Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012; 129(3): 628–634.
44. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 2003; 60(11): 1736–1737.
45. Wolberg AS, Kon RH, Monroe DM et al. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000; 65(1): 30–34.
46. Quinti I, Pierdominici M, Marziali M et al. European surveillance of immunoglobulin safety -results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries. Clin Immunol 2002; 104(3): 231–236.
47. Helbert MR, Bangs C, Bishop M et al. No evidence of asymptomatic variant CJD infection in immunodeficiency patients treated with UK-sourced immunoglobulin. Vox Sang 2016; 110(3): 282–284. Dostupné z DOI: <http://dx.doi.org/10.1111/vox.12358>.
51. Katz U, Achiron A, Sherer Y et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6(4): 257–259. Dostupné z DOI: <http://dx.doi.org/10.1016/j.autrev.2006.08.011>.
52. Jolles S, Orange JS, Gardulf A et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol 2015; 179(2): 146–160. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12485>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2019 Issue 2
Most read in this issue
- Anaphylactic symptoms and anaphylactic shock
- Current trends in immunosuppressive treatment
- Adverse effects of immunoglobulin therapy
- Primary immunodeficiencies in adults